VYNE Therapeutics (VYNE) Profit After Tax Growth (1y) (2017 - 2026)
VYNE Therapeutics (VYNE) Profit After Tax Growth (1y) (2017 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | 0.26% |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 17,802.13% |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 59.59% |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | -107.76% |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | 101.22% |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | - |
| 10 | VYNE Therapeutics | 1.19 Bn | 1.16 Bn | - | 58.46% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 58.46% |
| Jun 30, 2025 | 38.82% |
| Mar 31, 2025 | -38.30% |
| Dec 31, 2024 | -95.50% |
| Sep 30, 2024 | -83.25% |
| Jun 30, 2024 | 6.48% |
| Mar 31, 2024 | -11.21% |
| Dec 31, 2023 | 20.60% |
| Sep 30, 2023 | 28.86% |
| Jun 30, 2023 | -22.14% |
| Mar 31, 2023 | -220.17% |
| Dec 31, 2022 | -144.22% |
| Sep 30, 2022 | 56.52% |
| Jun 30, 2022 | 58.67% |
| Mar 31, 2022 | 142.94% |
| Dec 31, 2021 | 175.71% |
| Sep 30, 2021 | 13.87% |
| Jun 30, 2021 | 88.10% |
| Mar 31, 2021 | 72.97% |
| Dec 31, 2020 | -7.83% |